Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Priority Brief

Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia

Nicole E. Scharping, Ashley V. Menk, Ryan D. Whetstone, Xue Zeng and Greg M. Delgoffe
Nicole E. Scharping
1Tumor Microenvironment Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
2Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashley V. Menk
1Tumor Microenvironment Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan D. Whetstone
1Tumor Microenvironment Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
2Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xue Zeng
1Tumor Microenvironment Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Greg M. Delgoffe
1Tumor Microenvironment Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
2Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: delgoffeg@upmc.edu
DOI: 10.1158/2326-6066.CIR-16-0103 Published January 2017
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Tumor hypoxia is variable between tumor types and inhibits T-cell function. A, OCR trace of B16 and MC38 cells (50,000 cells/well) interrogated for mitochondrial activity in the Seahorse instrument. B, ECAR trace of B16 and MC38 cells interrogated for glycolytic activity in the Seahorse instrument. C, Hypoxyprobe staining of T cells isolated from B16 and MC38 tumors. Results are tabulated to the right. LN, lymph node. D, CellTrace Violet (CTV) dye dilution showing proliferation of OT-I T cells activated with peptide in ambient normoxia (20%) or hypoxic (1.5%) conditions. Shaded histogram, unstimulated cells. E, Cytokine production of CD8+ T cell stimulated as in D overnight. NS, no stimulation. F, Cytotoxicity [propidium iodide (PI) staining] of parental or OVA-expressing B16 tumor cells incubated with previously activated, effector OT-I T cells overnight under conditions of normoxia or hypoxia. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by unpaired t test (C and E) or two-way ANOVA with repeated measures (F). Results represent three independent experiments.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Metformin treatment acts as an inhibitor of tumor oxygen consumption. A, OCR of B16 or MC38 in vitro cultured cells (50,000 cells/well) treated overnight in the presence or absence of 10 mmol/L metformin. B, OCR of B16 tumor cells (CD45-depleted) plated directly ex vivo from mice bearing small tumors treated with PBS or metformin (Met; 50 mg/kg) for 3 days. C, Pimonidazole staining of full tumor sections (stitched from 300–500 individual panels) from mice bearing B16 tumors receiving PBS or metformin treatment for 3 days as in B. Tabulated results quantify the internal hypoxyprobe signal from a set threshold normalized for each day of imaging. Scale bar, 1 mm. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by unpaired t test. Data represent the mean (A–C tabulation) or are representative (C, images) of at least three independent experiments.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Metformin treatment reduces intratumoral T-cell hypoxia. A, OCR (top) or ECAR (bottom) from B16-bearing mice treated with metformin or vehicle for 3 days. CD45+CD8+ T cells were sorted by flow cytometry and assayed directly ex vivo, whereas B16 tumor cells were CD45-depleted before assaying. LN, lymph node. B, Flow cytogram (left) and tabulation (right) of pimonidazole staining in T cells from B16-bearing mice treated with metformin or vehicle for 3 days. C, Tumor area at 21 days for mice treated during tumor progression with PBS or metformin (Met). D and E, Quantification of CD44hi CD8+ T cells (D) from B16-bearing mice treated with metformin or vehicle for 3 days (E) PD-1 and Tim-3 expression in CD8+ T cells from mice treated as in D. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by unpaired t test. Results are representative of three (A, B, D, and E) or four (C) independent experiments.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Metabolic remodeling synergizes with checkpoint blockade to affect antitumor immunity. A, Tumor measurements of C57/BL6 mice inoculated with B16 melanoma. Mice began receiving treatment on day 5 as indicated, receiving 0.2 mg anti-PD-1 or its isotype control every 4 days, and either metformin (met) or vehicle. Number of mice tumor-free of the total inoculated is reported. B, Representative flow cytogram depicting IFNγ and TNFα production from CD8+ tumor-infiltrating T cells from B16-bearing mice treated as in A. C, Tabulated IFNγ staining from multiple mice; each dot represents one animal. D, Ki67 expression in CD8+ T cells from mice treated as in A as indicated. E, As in A, but mice were inoculated with MC38. **, P < 0.01; ***, P < 0.001 by unpaired t test. Results represent the mean (A, C, D, and E) or are representative of (B) three to five independent experiments.

Additional Files

  • Figures
  • Supplementary Data

    • Supplementary Figure Legends - Supplementary figure legends.
    • Supplementary Figure 1 - Metformin has indirect effects on immunity in the tumor microenvironment.
    • Supplementary Figure 2 - Metformin in the drinking water enhances PD-1 therapy in B16 melanoma.
PreviousNext
Back to top
Cancer Immunology Research: 5 (1)
January 2017
Volume 5, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
Nicole E. Scharping, Ashley V. Menk, Ryan D. Whetstone, Xue Zeng and Greg M. Delgoffe
Cancer Immunol Res January 1 2017 (5) (1) 9-16; DOI: 10.1158/2326-6066.CIR-16-0103

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
Nicole E. Scharping, Ashley V. Menk, Ryan D. Whetstone, Xue Zeng and Greg M. Delgoffe
Cancer Immunol Res January 1 2017 (5) (1) 9-16; DOI: 10.1158/2326-6066.CIR-16-0103
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Inducing CTLs through DLnano-vaccines to Target Cancer
  • Targeted Inhibitors Increase T-cell Activation
  • Remodeling Translation Primes T-cell Tumor Control
Show more Priority Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement